Recent Progress in Ferroptosis Inducers for Cancer Therapy
- PMID: 31595562
- DOI: 10.1002/adma.201904197
Recent Progress in Ferroptosis Inducers for Cancer Therapy
Abstract
Ferroptosis is a newly discovered form of regulated cell death that is the nexus between metabolism, redox biology, and human health. Emerging evidence shows the potential of triggering ferroptosis for cancer therapy, particularly for eradicating aggressive malignancies that are resistant to traditional therapies. Recently, there has been a great deal of effort to design and develop anticancer drugs based on ferroptosis induction. Recent advances of ferroptosis-inducing agents at the intersection of chemistry, materials science, and cancer biology are presented. The basis of ferroptosis is summarized first to highlight the feasibility and characteristics of triggering ferroptosis for cancer therapy. A literature review of ferroptosis inducers (including small molecules and nanomaterials) is then presented to delineate their design, action mechanisms, and anticancer applications. Finally, some considerations for research on ferroptosis inducers are spotlighted, followed by a discussion on the challenges and future development directions of this burgeoning field.
Keywords: cancer therapy; ferroptosis inducers; iron metabolism; nanomedicine; tumor microenvironment.
© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
Similar articles
-
Ferroptosis in cancer therapeutics: a materials chemistry perspective.J Mater Chem B. 2021 Nov 10;9(43):8906-8936. doi: 10.1039/d1tb01654g. J Mater Chem B. 2021. PMID: 34505861 Review.
-
Progress and Challenges in Tumor Ferroptosis Treatment Strategies: A Comprehensive Review of Metal Complexes and Nanomedicine.Small. 2024 Jun;20(25):e2310342. doi: 10.1002/smll.202310342. Epub 2024 Jan 14. Small. 2024. PMID: 38221682 Review.
-
Targeting Ferroptosis to Iron Out Cancer.Cancer Cell. 2019 Jun 10;35(6):830-849. doi: 10.1016/j.ccell.2019.04.002. Epub 2019 May 16. Cancer Cell. 2019. PMID: 31105042 Review.
-
Ferroptosis in Cancer Therapy: Mechanisms, Small Molecule Inducers, and Novel Approaches.Drug Des Devel Ther. 2024 Jun 21;18:2485-2529. doi: 10.2147/DDDT.S472178. eCollection 2024. Drug Des Devel Ther. 2024. PMID: 38919962 Free PMC article. Review.
-
Recent progress on nanomedicine-induced ferroptosis for cancer therapy.Biomater Sci. 2021 Aug 7;9(15):5092-5115. doi: 10.1039/d1bm00721a. Epub 2021 Jun 23. Biomater Sci. 2021. PMID: 34160488 Review.
Cited by
-
Immunotherapy-based novel nanoparticles in the treatment of gastrointestinal cancer: Trends and challenges.World J Gastroenterol. 2022 Oct 7;28(37):5403-5419. doi: 10.3748/wjg.v28.i37.5403. World J Gastroenterol. 2022. PMID: 36312831 Free PMC article. Review.
-
Circ-CDK8 regulates SLC7A11-mediated ferroptosis by inhibiting miR-615-5p to promote progression in oral squamous cell carcinomas.Front Pharmacol. 2024 Aug 7;15:1432520. doi: 10.3389/fphar.2024.1432520. eCollection 2024. Front Pharmacol. 2024. PMID: 39170701 Free PMC article.
-
Induction of pyroptotic cell death as a potential tool for cancer treatment.J Inflamm (Lond). 2022 Nov 14;19(1):19. doi: 10.1186/s12950-022-00316-9. J Inflamm (Lond). 2022. PMID: 36376979 Free PMC article. Review.
-
A ferroptosis associated gene signature for predicting prognosis and immune responses in patients with colorectal carcinoma.Front Genet. 2022 Sep 8;13:971364. doi: 10.3389/fgene.2022.971364. eCollection 2022. Front Genet. 2022. PMID: 36160009 Free PMC article.
-
Cholesterol Depletion-Enhanced Ferroptosis and Immunotherapy via Engineered Nanozyme.Adv Sci (Weinh). 2024 Oct;11(38):e2405826. doi: 10.1002/advs.202405826. Epub 2024 Aug 9. Adv Sci (Weinh). 2024. PMID: 39120559 Free PMC article.
References
-
- M. Gao, X. Jiang, Curr. Opin. Cell Biol. 2018, 51, 58.
-
- L. Galluzzi, I. Vitale, S. A. Aaronson, J. M. Abrams, D. Adam, P. Agostinis, E. S. Alnemri, L. Altucci, I. Amelio, D. W. Andrews, M. Annicchiarico-Petruzzelli, A. V. Antonov, E. Arama, E. H. Baehrecke, N. A. Barlev, N. G. Bazan, F. Bernassola, M. J. M. Bertrand, K. Bianchi, M. V. Blagosklonny, K. Blomgren, C. Borner, P. Boya, C. Brenner, M. Campanella, E. Candi, D. Carmona-Gutierrez, F. Cecconi, F. K.-M. Chan, N. S. Chandel, E. H. Cheng, J. E. Chipuk, J. A. Cidlowski, A. Ciechanover, G. M. Cohen, M. Conrad, J. R. Cubillos-Ruiz, P. E. Czabotar, V. D'Angiolella, T. M. Dawson, V. L. Dawson, V. D. Laurenzi, R. D. Maria, K.-M. Debatin, R. J. DeBerardinis, M. Deshmukh, N. D. Daniele, F. D. Virgilio, V. M. Dixit, S. J. Dixon, C. S. Duckett, B. D. Dynlacht, W. S. El-Deiry, J. W. Elrod, G. M. Fimia, S. Fulda, A. J. García-Sáez, A. D. Garg, C. Garrido, E. Gavathiotis, P. Golstein, E. Gottlieb, D. R. Green, L. A. Greene, H. Gronemeyer, A. Gross, G. Hajnoczky, J. M. Hardwick, I. S. Harris, M. O. Hengartner, C. Hetz, H. Ichijo, M. Jäättelä, B. Joseph, P. J. Jost, P. P. Juin, W. J. Kaiser, M. Karin, T. Kaufmann, O. Kepp, A. Kimchi, R. N. Kitsis, D. J. Klionsky, R. A. Knight, S. Kumar, S. W. Lee, J. J. Lemasters, B. Levine, A. Linkermann, S. A. Lipton, R. A. Lockshin, C. López-Otín, S. W. Lowe, T. Luedde, E. Lugli, M. MacFarlane, F. Madeo, M. Malewicz, W. Malorni, G. Manic, J.-C. Marine, S. J. Martin, J.-C. Martinou, J. P. Medema, P. Mehlen, P. Meier, S. Melino, E. A. Miao, J. D. Molkentin, U. M. Moll, C. Muñoz-Pinedo, S. Nagata, G. Nuñez, A. Oberst, M. Oren, M. Overholtzer, M. Pagano, T. Panaretakis, M. Pasparakis, J. M. Penninger, D. M. Pereira, S. Pervaiz, M. E. Peter, M. Piacentini, P. Pinton, J. H. M. Prehn, H. Puthalakath, G. A. Rabinovich, M. Rehm, R. Rizzuto, C. M. P. Rodrigues, D. C. Rubinsztein, T. Rudel, K. M. Ryan, E. Sayan, L. Scorrano, F. Shao, Y. Shi, J. Silke, H.-U. Simon, A. Sistigu, B. R. Stockwell, A. Strasser, G. Szabadkai, S. W. G. Tait, D. Tang, N. Tavernarakis, A. Thorburn, Y. Tsujimoto, B. Turk, T. V. Berghe, P. Vandenabeele, M. G. V. Heiden, A. Villunger, H. W. Virgin, K. H. Vousden, D. Vucic, E. F. Wagner, H. Walczak, D. Wallach, Y. Wang, J. A. Wells, W. Wood, J. Yuan, Z. Zakeri, B. Zhivotovsky, L. Zitvogel, G. Melino, G. Kroemer, Cell Death Differ. 2018, 25, 486.
-
- L. R. Parisi, L. M. Morrow, M. B. Visser, G. E. Atilla-Gokcumen, ACS Chem. Biol. 2018, 13, 506.
-
- D. R. Green, Cell 2019, 177, 1094.
-
- J. P. F. Angeli, R. Shah, D. A. Pratt, M. Conrad, Trends Pharmacol. Sci. 2017, 38, 489.
Publication types
MeSH terms
Substances
Grants and funding
- 61525402/National Natural Science Foundation of China
- 61775095/National Natural Science Foundation of China
- BE2017741/Jiangsu Provincial key research and development plan
- 2017B020226001/Guangdong Provincial Science and Technology Project
- JCYJ20170818095453642/Basic Research Projects of Shenzhen Knowledge Innovation Program
LinkOut - more resources
Full Text Sources